nach oben

Drugs

Erschienen in:

01.06.2019 | AdisInsight Report

Peficitinib: First Global Approval

verfasst von: Anthony Markham, Susan J. Keam

Erschienen in: Drugs | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Peficitinib [Smyraf^® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in rheumatoid arthritis. Peficitinib has been shown to significantly improve ACR20 and other measures of disease severity and to reduce the mean modified total Sharp score change from baseline in clinical trials. This article summarizes the milestones in the development of peficitinib leading to this first approval as a treatment for rheumatoid arthritis in patients who have an inadequate response to conventional therapies.

Astellas Pharma. Oral JAK inhibitor Smyraf^® tablets approved in Japan for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have an inadequate response to conventional therapies [media release]. 26 Mar 2019. https://www.astellas.com/en/news/14651.

Astellas Pharma. Smyraf^® tablets 50 mg and 100 mg: prescribing information. 2019. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/800126_39990C6F1020_1_03. Accessed 1 Apr 2019.

Janssen Biotech. Janssen announces worldwide agreement to develop and commercialize JAK inhibitor for immunological diseases [media release]. 1 Oct 2012. http://www.janssenbiotech.com.

Astellas Pharma. Astellas announces end of license agreement with Janssen to develop and commercialize ASP015K [media release]. 2 Dec 2014. http://www.astellas.com.

Ito M, Yamazaki S, Yamagami K, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017;133(1):25–33.CrossRefPubMed

Higashi Y, Inami M, Ito M, et al. ASP015K: a novel JAK inhibitor demonstrated potent efficacy in a chronic oxazolone-induced dermatitis model in rats [abstract no. P093]. Dermatol Ther. 2012;2(Suppl):S41–2.

Cao YJ, Sawamoto T, Valluri U, et al. Pharmacokinetics, pharmacodynamics, and safety of ASP015K (peficitinib), a new janus kinase inhibitor, in healthy subjects. Clin Pharmacol Drug Dev. 2016;5(6):435–49.CrossRefPubMed

Zhu T, Howieson C, Wojtkowski T, et al. The effect of verapamil, a p-glycoprotein inhibitor, on the pharmacokinetics of peficitinib, an orally administered, once-daily JAK inhibitor. Clin Pharmacol Drug Dev. 2017;6(6):548–55.CrossRefPubMed

Zhu T, Oda K, Valluri U, et al. Coadministration of ASP015K, a novel janus kinase inhibitor, with methotrexate demonstrates tolerability and lack of pharmacokinetic interactions in patients with rheumatoid arthritis [abstract no. AB0363]. Ann Rheum Dis. 2013;72(Suppl. 3):898.

10.

Zhu T, Parker B, Wojtkowski T, et al. Drug interactions between peficitinib, an orally administered, once-daily janus kinase inhibitor, and rosuvastatin in healthy subjects. Clin Pharmacokinet. 2017;56(7):747–57.CrossRefPubMed

11.

Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of the novel oral Janus kinase (JAK) inhibitor, peficitinib (ASP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with RA who had an inadequate response to Dmards [abstract no. 887]. Arthritis Rheumatol. 2018;70(Suppl. 9):983–4.

12.

Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of the novel oral Janus kinase (JAK) inhibitor, peficitinib (ASP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with RA who had an inadequate response to methotrexate [abstract no. 888]. Arthritis Rheumatol. 2018;70(Suppl. 9):985–6.

13.

Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75(6):1057–64.CrossRefPubMed

14.

Genovese MC, Greenwald M, Codding C, et al. Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017;69(5):932–42.CrossRefPubMed

15.

Kivitz AJ, Gutierrez-Urena SR, Poiley J, et al. Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol. 2017;69(4):709–19.CrossRefPubMed

Titel: Peficitinib: First Global Approval
verfasst von: Anthony Markham
Susan J. Keam
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 8/2019
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-019-01131-y

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Peficitinib: First Global Approval

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Teriflunomide: A Review in Relapsing–Remitting Multiple Sclerosis

Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy

Risankizumab: First Global Approval

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer

Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?

Drugs in Development for Acute Kidney Injury